Status | Study |
COMPLETED |
Study Name: Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease Condition: Fabry Disease Date: 2016-04-15 |
Recruiting |
Study Name: Lipidomics and Functional Analyses of Platelets in Fabry Disease Condition: Fabry Disease Date: 2015-12-06 |
Active, not recruiting |
Study Name: Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease Condition: Fabry Disease Date: 2014-07-17 Interventions: Drug: migalastat HCl 150 mg Capsule provided in 14-day supply blister packs. Migalastat HCl is taken eve |
Terminated |
Study Name: A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease Condition: Fabry Disease Date: 2013-04-11 Interventions: Drug: Iohexol Evaluations of renal and cardiac function are standard-of-care in young patients with Fabr |
Completed |
Study Name: Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta Condition: Fabry Disease Date: 2012-12-05 |
Recruiting |
Study Name: Home Therapy With Replagal in Fabry Disease Condition: Fabry Disease Date: 2011-05-16 |
Completed |
Study Name: Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Condition: Fabry Disease Date: 2010-10-06 Interventions: Drug: migalastat hydrochloride |
Completed |
Study Name: Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease Condition: Fabry Disease Date: 2010-09-07 Interventions: Drug: AT1001 Capsules, single dose Other Name: migal |
Completed |
Study Name: Establishment of Biomarkers for Fabry Disease Condition: Fabry Disease Date: 2010-07-16 Interventions: Other: Fluorescein angiography Fluorescein angiography once every 6 months for 3 years |
Completed |
Study Name: Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study Condition: Fabry Disease Date: 2007-09-05 Interventions: Drug: AT1001 AT1001 |